Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FPR3 | P25089 | 4/20 | 0.38 |
| ▸ | FPR2 | P25090 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25361465 | 1.00 | KDM4E (0.53) | KDM4ELMNAEPHX2ESR1PAOX | |
| SCHEMBL17888049 | 0.89 | EPHX2 (0.43) | KDM4ELMNAEPHX2ESR1PAOX | |
| SCHEMBL9924679 | 0.88 | KDM4E (0.59) | KDM4ELMNAEPHX2ESR1NPC1 | |
| SCHEMBL25361995 | 0.87 | KDM4E (0.54) | KDM4ELMNAEPHX2ESR1NPC1 | |
| SCHEMBL21389659 | 0.85 | KDM4E (0.53) | KDM4ELMNAEPHX2ESR1 | |
| SCHEMBL19786751 | 0.85 | KDM4E (0.53) | KDM4ELMNAEPHX2ESR1 | |
| SCHEMBL14611026 | 0.84 | KDM4E (0.46) | KDM4ELMNAEPHX2ESR1NPC1 | |
| SCHEMBL5395258 | 0.82 | KDM4E (0.56) | KDM4ELMNAEPHX2ESR1TLR2 | |
| SCHEMBL25362014 | 0.80 | ESR1 (0.48) | KDM4ELMNAEPHX2ESR1NPC1 | |
| SCHEMBL26031798 | 0.80 | ESR1 (0.48) | KDM4ELMNAEPHX2ESR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786603-B2 | Optimized transglutaminase site-specific antibody conjugation | REGENERON PHARMACEUTICALS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11786603-B2 | Optimized transglutaminase site-specific antibody conjugation | REGENERON PHARMACEUTICALS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| EP-3010547-B1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | INNATE PHARMA (FR) | 2021-04-21 | — | — | EP | disclosed |
| EP-2793947-B1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | INNATE PHARMA (FR) | 2021-02-03 | — | — | EP | disclosed |
| US-10675359-B2 | Enzymatic conjugation of antibodies | INNATE PHARMA (FR) | 2020-06-09 | — | — | US | disclosed |
| US-10611824-B2 | Solid phase TGase-mediated conjugation of antibodies | INNATE PHARMA (FR) | 2020-04-07 | — | — | US | disclosed |
| US-10434180-B2 | Enzymatic conjugation of polypeptides | INNATE PHARMA (FR) | 2019-10-08 | — | — | US | disclosed |
| US-20190169601-A1 | RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION | INNATE PHARMA (FR) | 2019-06-06 | — | — | US | disclosed |
| US-20190070306-A1 | OPTIMIZED TRANSGLUTAMINASE SITE-SPECIFIC ANTIBODY CONJUGATION | REGENERON PHARMACEUTICALS, INC. | 2019-03-07 | — | — | US | disclosed |
| US-10036010-B2 | Recognition tags for TGase-mediated conjugation | INNATE PHARMA (FR) | 2018-07-31 | — | — | US | disclosed |
| US-20150284713-A1 | RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION | ARARIS BIOTECH LTD (CH) | 2015-10-08 | — | — | US | disclosed |
| US-20150284713-A1 | RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION | ARARIS BIOTECH LTD (CH) | 2015-10-08 | — | — | US | disclosed |
| US-20150165064-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | ARARIS BIOTECH LTD (CH) | 2015-06-18 | — | — | US | disclosed |
| US-20150165064-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | ARARIS BIOTECH LTD (CH) | 2015-06-18 | — | — | US | disclosed |
| US-20140356385-A1 | ENZYMATIC CONJUGATION OF ANTIBODIES | ARARIS BIOTECH LTD (CH) | 2014-12-04 | — | — | US | disclosed |
| US-20140356385-A1 | ENZYMATIC CONJUGATION OF ANTIBODIES | ARARIS BIOTECH LTD (CH) | 2014-12-04 | — | — | US | disclosed |
| WO-2014072482-A1 | RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION | INNATE PHARMA (FR) | 2014-05-15 | — | — | WO | disclosed |
| US-20130189287-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | PAUL SCHERRER INSTITUT | 2013-07-25 | — | — | US | disclosed |
| US-20130189287-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | PAUL SCHERRER INSTITUT | 2013-07-25 | — | — | US | disclosed |
| WO-2013092998-A1 | ENZYMATIC CONJUGATION OF ANTIBODIES | INNATE PHARMA (FR) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10675359-B2 | Enzymatic conjugation of antibodies | DNPEP, MPO, FCGR3B | KDM4E 3043/4885LMNA 4260/4885EPHX2 618/4885 |
| US-20130189287-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | DNPEP, ENPEP, PEPD | KDM4E 4378/4885LMNA 3801/4885EPHX2 937/4885 |
| US-10611824-B2 | Solid phase TGase-mediated conjugation of antibodies | TGM3, TGM2, TGM6 | KDM4E 783/4885LMNA 4126/4885EPHX2 1500/4885 |
| US-10434180-B2 | Enzymatic conjugation of polypeptides | DNPEP, ENPEP, PEPD | KDM4E 4100/4885LMNA 3847/4885EPHX2 876/4885 |
| US-10036010-B2 | Recognition tags for TGase-mediated conjugation | TGM2, TGM3, TGM6 | KDM4E 2005/4885LMNA 4672/4885EPHX2 952/4885 |
| US-20140356385-A1 | ENZYMATIC CONJUGATION OF ANTIBODIES | DNPEP, MPO, FCGR3B | KDM4E 3043/4885LMNA 4260/4885EPHX2 618/4885 |
| US-11786603-B2 | Optimized transglutaminase site-specific antibody conjugation | TGM2, TGM3, TGM1 | KDM4E 1627/4885LMNA 3147/4885EPHX2 934/4885 |
| US-20150284713-A1 | RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION | TGM2, TGM3, TGM6 | KDM4E 2005/4885LMNA 4672/4885EPHX2 952/4885 |
| US-20190169601-A1 | RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION | TGM2, TGM3, TGM6 | KDM4E 2005/4885LMNA 4672/4885EPHX2 952/4885 |
| US-20190070306-A1 | OPTIMIZED TRANSGLUTAMINASE SITE-SPECIFIC ANTIBODY CONJUGATION | TGM2, TGM3, TGM1 | KDM4E 1627/4885LMNA 3147/4885EPHX2 934/4885 |
| US-20150165064-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | DNPEP, ENPEP, PEPD | KDM4E 4100/4885LMNA 3847/4885EPHX2 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.